ELAVL1 and diabetic retinopathy: Among the viable drug delivery routes utilized to suppress VEGF-mediated angiogenesis, lipidic nanocarriers have been engineered to silence the expression of the human antigen R (HuR/Elavl1), encoding an RNA-binding protein known to be involved in diabetic retinopathy, suggesting a similar approach could be leveraged for the treatment of wet age-related macular degeneration and diabetic macular oedema [255].